Skip to content

Impact of Nasopharyngeal Airway Combined with High - flow Nasal Cannula on Respiratory Adverse Events during Painless Gastroscopy and Colonoscopy in Obese Patients

Impact of Nasopharyngeal Airway Combined with Nasal High-Flow Oxygen Therapy on Respiratory Adverse Events in Obese Patients Undergoing Painless Gastrointestinal Endoscopy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500109995
Enrollment
Unknown
Registered
2025-09-28
Start date
2025-09-30
Completion date
Unknown
Last updated
2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory system adverse events

Interventions

Control group:Administer oxygen via a standard nasal cannula: Secure the standard nasal cannula in the nasal vestibule and deliver oxygen at a flow rate of 6 L/min, then initiate intravenous anesthesi
Nasopharyngeal airway group:Administer oxygen via a nasal cannula: Secure a standard nasal cannula in the nasal vestibule and deliver oxygen at 6 L/min. Initiate intravenous anesthesia. Once adequate
High-traffic group:Administer high-flow nasal cannula (HFNC) oxygen: Secure the high-flow nasal oxygen device in the nasal vestibule and initiate oxygen delivery at 30 L/min. Begin intravenous anesthe
Nasal-pharyngeal combined high-flow group:Secure the high-flow nasal cannula in the nasal vestibule and deliver oxygen at 30 L/min. Initiate intravenous anesthesia. Once adequate anesthesia is achieve

Sponsors

East Campus of Baoding First Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1 ASA classification grade I or II; 2 Age 18-75 years old; 3 BMI>=28 Kg/m^2; 4 Approved by the hospital ethics committee and signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1 Severe cardiopulmonary, hepatic, or renal insufficiency; 2 Not fasting or having a full stomach; 3 Severe coagulation dysfunction, bleeding tendency, or during anticoagulant therapy; 4 Nasal masses or hemangiomas, severe maxillary trauma, or skull base fractures; 5 Diagnosed with respiratory diseases, including asthma, bronchitis, chronic obstructive pulmonary disease, pulmonary bulla, pulmonary embolism, pulmonary edema, etc; 6 Allergic to general anesthetics or unable to tolerate them.

Design outcomes

Primary

MeasureTime frame
Adverse events of the respiratory system;

Secondary

MeasureTime frame
Nausea and vomiting;Nasopharyngeal pain;Dizziness;Dry mouth;Incidence rate of subclinical respiratory depression;Satisfaction of Endoscopists;hypotension;Hypertension;

Countries

China

Contacts

Public ContactBian Qian

The First Central Hospital of Baoding City

bianqian1991@163.com+86 133 9860 9621

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026